The role of the orexin system in the neurobiology of anxiety disorders: Potential for a novel treatment target
Rattachement africain : gb, de, Afrique du Sud. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Anxiety disorders constitute the most common group of psychiatric disorders with a lifetime prevalence of 14.5-33.7%. Despite efficacious pharmacological and psychological treatments, first line treatment is often not effective, and development of new therapies is needed. One area of interest is the orexin system, a neurotransmitter system centred in the lateral hypothalamus with widespread projections throughout the brain, including to several key areas involved in the modulation of fear and anxiety. In this article, we summarise findings from pre-clinical and clinical investigations of the potential role of the orexin system in the neurobiology of fear and anxiety. Pre-clinical studies in rodents generally indicate that orexin signalling promotes fear and anxiety-related behaviour, particularly in response to aversive stimuli. Orexin signalling in the amygdala, bed nucleus of the stria terminalis, paraventricular nucleus of thalamus, locus coeruleus and prefrontal cortex has been specifically implicated. Human studies are limited, with some evidence that orexin receptor antagonists are anxiolytic in experimental medicine models of anxiety, some indications from clinical populations of altered orexin signalling, and a molecular genetic study associating a non-synonymous variant in the orexin 1 receptor (HCRTR1) with panic disorder and agoraphobia. Given this emerging body of evidence, further human studies are required to fully assess the orexin system as a potential novel anxiolytic target.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- The role of the orexin system in the neurobiology of anxiety disorders: Potential for a novel treatment target
- Date Crossref
- 01/01/2024
- Éditeur
- Elsevier BV
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Southern Health NHS Foundation Trust pays non établi dans la noticeÉtablissement de santé
-
University of Southampton pays non établi dans la noticeUniversité ou école supérieure
-
University of Freiburg Department of Psychiatry and Psychotherapy pays non établi dans la noticeUniversité ou école supérieure
-
University of Cape Town Department of Psychiatry and Mental Health University of Cape Town, Afrique du Sud (code pays fourni par la source)Université ou école supérieure
-
Faculty of Medicine Clinical and Experimental Sciences (CNS and Psychiatry) pays non établi dans la noticeUniversité ou école supérieure
Southern Health NHS Foundation Trust, University of Southampton et Department of Psychiatry and Psychotherapy — University of Freiburg, avec 2 autres affiliations. Pays d’affiliation : Afrique du Sud.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.